相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
Martin A. Maier et al.
MOLECULAR THERAPY (2013)
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
Teresa Coelho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
NADPH-Cytochrome P450 Oxidoreductase: Roles in Physiology, Pharmacology, and Toxicology
David S. Riddick et al.
DRUG METABOLISM AND DISPOSITION (2013)
Evidence That Cytochrome b5 and Cytochrome b5 Reductase Can Act as Sole Electron Donors to the Hepatic Cytochrome P450 Systems
Colin J. Henderson et al.
MOLECULAR PHARMACOLOGY (2013)
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo
Muthusamy Jayaraman et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Challenges in the pharmaceutical development of lipid-based short interfering ribonucleic acid therapeutics
Marian E. Gindy et al.
EXPERT OPINION ON DRUG DELIVERY (2012)
siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids
Marija Tadin-Strapps et al.
JOURNAL OF LIPID RESEARCH (2011)
Deletion of Microsomal Cytochrome b5 Profoundly Affects Hepatic and Extrahepatic Drug Metabolism
Lesley A. McLaughlin et al.
MOLECULAR PHARMACOLOGY (2010)
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
Akin Akinc et al.
MOLECULAR THERAPY (2010)
Rational design of cationic lipids for siRNA delivery
Sean C. Semple et al.
NATURE BIOTECHNOLOGY (2010)
Is 1-Aminobenzotriazole an Appropriate in Vitro Tool as a Nonspecific Cytochrome P450 Inactivator?
Collette D. Linder et al.
DRUG METABOLISM AND DISPOSITION (2009)
Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats
Jun Shik Choi et al.
ARCHIVES OF PHARMACAL RESEARCH (2008)
Defining the in Vivo Role for Cytochrome b5 in Cytochrome P450 Function through the Conditional Hepatic Deletion of Microsomal Cytochrome b5
Robert D. Finn et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Cytochrome b5 increases the rate of product formation by cytochrome p450 2B4 and competes with cytochrome p450 reductase for a binding site on cytochrome p450 2B4
Haoming Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: Varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance
Timothy J. Strelevitz et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Structure and chemistry of cytochrome P450
IG Denisov et al.
CHEMICAL REVIEWS (2005)
Liver-specific deletion of the NADPH-cytochrome P450 reductase gene - Impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase
J Gu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase
CJ Henderson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: Role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide
S Kumar et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat
T Kotegawa et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome p450 oxidoreductase
AL Shen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat
K Kobayashi et al.
BIOCHEMICAL PHARMACOLOGY (2002)